EULAR 2019: Lilly's Taltz bests Humira in PsA

13 June 2019
lilly-location-big-1

US pharma major Eli Lilly (NYSE: LLY) presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s (NYSE: ABBV) Humira (adalimumab) in active psoriatic arthritis (PsA).

The primary endpoint of the study was superiority for Taltz in the proportion of patients who simultaneously achieved a reduction by at least 50% in disease activity, and complete skin clearance for psoriasis.

At 24 weeks, the proportion of patients achieving a reduction in both measures was significantly higher for Taltz, at 36% compared to Humira’s 28%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology